Enhancement of the therapeutic index : From non myeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancerDENARDO, Sally J; RICHMAN, Carol M; ALBRECHT, Huguette et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 7187s-7194s, issn 1078-0432, 2Conference Paper

Antiangiogenic agents and their promising potential in combined therapyBURKE, Patricia A; DENARDO, Sally J.Critical reviews in oncology/hematology. 2001, Vol 39, Num 1-2, pp 155-171, issn 1040-8428Conference Paper

Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy : Initial application to lymphoma/leukemiaBALHORN, Rod; HOK, Saphon; DENARDO, Sally J et al.Clinical cancer research. 2007, Vol 13, Num 18, issn 1078-0432, 5621s-5628s, 2Conference Paper

Cilengitide targeting of α_vβ₃ integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenograftsBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer research (Baltimore). 2002, Vol 62, Num 15, pp 4263-4272, issn 0008-5472Article

Combined modality radioimmunotherapy: Promise and perilBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer. 2002, Vol 94, Num 4, pp 1320-1331, issn 0008-543X, SUPConference Paper

Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting moleculesBURKE, Patricia. A; GREGG, Jeffrey P; BAKHTIAR, Brandon et al.International journal of oncology. 2006, Vol 29, Num 1, pp 49-55, issn 1019-6439, 7 p.Article